191 related articles for article (PubMed ID: 37812926)
1. Cellular Therapy in Chronic Lymphocytic Leukemia: Have We Advanced in the Last Decade?
Katz OB; Yehudai-Ofir D; Zuckerman T
Acta Haematol; 2024; 147(1):99-112. PubMed ID: 37812926
[TBL] [Abstract][Full Text] [Related]
2. Is There a Role for Cellular Therapy in Chronic Lymphocytic Leukemia?
Dreger P
Cancer J; 2021 Jul-Aug 01; 27(4):297-305. PubMed ID: 34398556
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T Cells in Chronic Lymphocytic Leukemia: Are We Any Closer to a Cure?
Rhodes JM; Schuster SJ
Cancer J; 2019; 25(6):436-441. PubMed ID: 31764125
[TBL] [Abstract][Full Text] [Related]
4. Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia.
Bair SM; Porter DL
Am J Hematol; 2019 May; 94(S1):S10-S17. PubMed ID: 30861173
[TBL] [Abstract][Full Text] [Related]
5. Cellular Therapy Advances in Chronic Lymphocytic Leukemia and Richter's Syndrome.
Bajwa A; Voorhees TJ; Kittai AS
Curr Probl Cancer; 2022 Feb; 46(1):100827. PubMed ID: 34991902
[TBL] [Abstract][Full Text] [Related]
6. Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cells.
Yang S; Huang X; Gale RP
Blood Rev; 2022 Jan; 51():100884. PubMed ID: 34489116
[TBL] [Abstract][Full Text] [Related]
7. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.
Fraietta JA; Schwab RD; Maus MV
Semin Oncol; 2016 Apr; 43(2):291-9. PubMed ID: 27040708
[TBL] [Abstract][Full Text] [Related]
8. The use of chimeric antigen T-cell therapy in chronic lymphocytic leukemia.
Siddiqi T
Clin Adv Hematol Oncol; 2022 Jun; 20(6):366-368. PubMed ID: 35731607
[No Abstract] [Full Text] [Related]
9. Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond.
Shadman M; Maloney DG
Hematol Oncol Clin North Am; 2021 Aug; 35(4):847-862. PubMed ID: 34174989
[TBL] [Abstract][Full Text] [Related]
10. Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia.
Kovalovsky D; Yoon JH; Cyr MG; Simon S; Voynova E; Rader C; Wiestner A; Alejo J; Pittaluga S; Gress RE
Leukemia; 2021 Sep; 35(9):2581-2591. PubMed ID: 33633313
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
12. Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned.
Can I; Cox MJ; Siegler EL; Sakemura R; Kenderian SS
Exp Hematol; 2022 Apr; 108():1-7. PubMed ID: 35150777
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia.
Zou Y; Xu W; Li J
J Hematol Oncol; 2018 Nov; 11(1):130. PubMed ID: 30458878
[TBL] [Abstract][Full Text] [Related]
14. Insights into Chimeric Antigen Receptor Therapy for Chronic Lymphoblastic Leukemia.
Hamieh M; Sadelain M
Trends Mol Med; 2018 Sep; 24(9):729-731. PubMed ID: 30149852
[TBL] [Abstract][Full Text] [Related]
15. Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia.
Mancikova V; Smida M
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073911
[TBL] [Abstract][Full Text] [Related]
16. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia.
Cox MJ; Lucien F; Sakemura R; Boysen JC; Kim Y; Horvei P; Manriquez Roman C; Hansen MJ; Tapper EE; Siegler EL; Forsman C; Crotts SB; Schick KJ; Hefazi M; Ruff MW; Can I; Adada M; Bezerra E; Kankeu Fonkoua LA; Nevala WK; Braggio E; Ding W; Parikh SA; Kay NE; Kenderian SS
Mol Ther; 2021 Apr; 29(4):1529-1540. PubMed ID: 33388419
[TBL] [Abstract][Full Text] [Related]
17. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
Singh N; Frey NV; Grupp SA; Maude SL
Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
[TBL] [Abstract][Full Text] [Related]
18. Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.
Shadman M; Gauthier J; Hay KA; Voutsinas JM; Milano F; Li A; Hirayama AV; Sorror ML; Cherian S; Chen X; Cassaday RD; Till BG; Gopal AK; Sandmaier BM; Maloney DG; Turtle CJ
Blood Adv; 2019 Oct; 3(20):3062-3069. PubMed ID: 31648329
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells.
Faitschuk E; Hombach AA; Frenzel LP; Wendtner CM; Abken H
Blood; 2016 Sep; 128(13):1711-22. PubMed ID: 27535994
[TBL] [Abstract][Full Text] [Related]
20. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
